30 related articles for article (PubMed ID: 28678239)
1. Surface Modification of Mesoporous Silica Nanoparticles for Application in Targeted Delivery Systems of Antitumour Drugs.
Kovtareva S; Kusepova L; Tazhkenova G; Mashan T; Bazarbaeva K; Kopishev E
Polymers (Basel); 2024 Apr; 16(8):. PubMed ID: 38675024
[TBL] [Abstract][Full Text] [Related]
2. State of the Art of Silica Nanoparticles: An Overview on Biodistribution and Preclinical Toxicity Studies.
Yu J; Dan N; Eslami SM; Lu X
AAPS J; 2024 Mar; 26(3):35. PubMed ID: 38514482
[TBL] [Abstract][Full Text] [Related]
3. Confinement and Polarity Effects on the Peptide Packing Density on Mesoporous Silica Nanoparticles.
Beitzinger B; Schmid R; Jung C; Tiwary K; Hermann P; Jacob T; Lindén M
Langmuir; 2024 Feb; 40(8):4294-4305. PubMed ID: 38346113
[TBL] [Abstract][Full Text] [Related]
4. Surface functionalization affects the retention and bio-distribution of orally administered mesoporous silica nanoparticles in a colitis mouse model.
Schmid R; Volcic M; Fischer S; Qu Z; Barth H; Popat A; Kirchhoff F; Lindén M
Sci Rep; 2023 Nov; 13(1):20175. PubMed ID: 37978264
[TBL] [Abstract][Full Text] [Related]
5. Natural Biopolymers as Smart Coating Materials of Mesoporous Silica Nanoparticles for Drug Delivery.
Dumontel B; Conejo-Rodríguez V; Vallet-Regí M; Manzano M
Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839771
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the EPR Effect in the CAM-Model by Molecular Imaging with MRI and PET Using
Hilbrig C; Löffler J; Fischer G; Scheidhauer E; Solbach C; Huber-Lang M; Beer AJ; Rasche V; Winter G
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831469
[TBL] [Abstract][Full Text] [Related]
7. Preclinical PET and MR Evaluation of
Winter G; Eberhardt N; Löffler J; Raabe M; Alam MNA; Hao L; Abaei A; Herrmann H; Kuntner C; Glatting G; Solbach C; Jelezko F; Weil T; Beer AJ; Rasche V
Nanomaterials (Basel); 2022 Dec; 12(24):. PubMed ID: 36558325
[TBL] [Abstract][Full Text] [Related]
8. Blocking Studies to Evaluate Receptor-Specific Radioligand Binding in the CAM Model by PET and MR Imaging.
Löffler J; Herrmann H; Scheidhauer E; Wirth M; Wasserloos A; Solbach C; Glatting G; Beer AJ; Rasche V; Winter G
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010864
[TBL] [Abstract][Full Text] [Related]
9. Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?
Vallet-Regí M; Schüth F; Lozano D; Colilla M; Manzano M
Chem Soc Rev; 2022 Jul; 51(13):5365-5451. PubMed ID: 35642539
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Quantification of Target-Specific Accumulation of [
Löffler J; Hamp C; Scheidhauer E; Di Carlo D; Solbach C; Abaei A; Hao L; Glatting G; Beer AJ; Rasche V; Winter G
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439163
[TBL] [Abstract][Full Text] [Related]
11. Biosafety of mesoporous silica nanoparticles: a combined experimental and literature study.
Sun L; Sogo Y; Wang X; Ito A
J Mater Sci Mater Med; 2021 Aug; 32(9):102. PubMed ID: 34406531
[TBL] [Abstract][Full Text] [Related]
12. Multi-Modal PET and MR Imaging in the Hen's Egg Test-Chorioallantoic Membrane (HET-CAM) Model for Initial
Winter G; Koch ABF; Löffler J; Lindén M; Solbach C; Abaei A; Li H; Glatting G; Beer AJ; Rasche V
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429233
[TBL] [Abstract][Full Text] [Related]
13. Mesoporous Silica Nanoparticles for the Treatment of Complex Bone Diseases: Bone Cancer, Bone Infection and Osteoporosis.
Gisbert-Garzarán M; Manzano M; Vallet-Regí M
Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31968690
[TBL] [Abstract][Full Text] [Related]
14. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update.
Castillo RR; Lozano D; González B; Manzano M; Izquierdo-Barba I; Vallet-Regí M
Expert Opin Drug Deliv; 2019 Apr; 16(4):415-439. PubMed ID: 30897978
[TBL] [Abstract][Full Text] [Related]
15. Quantitative and correlative biodistribution analysis of
Kramer L; Winter G; Baur B; Kuntz AJ; Kull T; Solbach C; Beer AJ; Lindén M
Nanoscale; 2017 Jul; 9(27):9743-9753. PubMed ID: 28678239
[TBL] [Abstract][Full Text] [Related]
16. In Vivo Integrity and Biological Fate of Chelator-Free Zirconium-89-Labeled Mesoporous Silica Nanoparticles.
Chen F; Goel S; Valdovinos HF; Luo H; Hernandez R; Barnhart TE; Cai W
ACS Nano; 2015 Aug; 9(8):7950-9. PubMed ID: 26213260
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, characterization, and biodistribution of multiple 89Zr-labeled pore-expanded mesoporous silica nanoparticles for PET.
Miller L; Winter G; Baur B; Witulla B; Solbach C; Reske S; Lindén M
Nanoscale; 2014 May; 6(9):4928-35. PubMed ID: 24675844
[TBL] [Abstract][Full Text] [Related]
18. Etoposide encased folic acid adorned mesoporous silica nanoparticles as potent nanovehicles for enhanced prostate cancer therapy: synthesis, characterization, cellular uptake and biodistribution.
Saroj S; Rajput SJ
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S1115-S1130. PubMed ID: 30669865
[TBL] [Abstract][Full Text] [Related]
19. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
